I mean, it’s just a value proposition determination.
I am by no means certain this is what is happening. And in the case it is approved, which I still give a more than credible probability to, the value is enough to outweigh the risk of non approval in my opinion.
That’s how any prerev biotech investment works. Nobody is certain of outcomes either way.